The UK Competition Authority announces that several firms have been fined a total of over £35M for an anti-competitive arrangement in the supply of important National Health Service prescription anti-nausea tablets (Alliance Pharmaceuticals / Focus / Lexon)

On 3 February 2022, the UK Competition and Markets Authority (CMA) announced that – following an investigation into the conduct of several pharmaceutical firms – it had fined several firms a total of over £35 million for an anti-competitive arrangement in the supply of important National Health Service (NHS) prescription anti-nausea tablets. Whilst the CMA’s decision has so far only been announced, and it is therefore currently difficult to comment on the specifics of the investigation, the CMA’s press release

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Citation

Michael Clancy, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The UK Competition Authority announces that several firms have been fined a total of over £35M for an anti-competitive arrangement in the supply of important National Health Service prescription anti-nausea tablets (Alliance Pharmaceuticals / Focus / Lexon), 3 février 2022, e-Competitions February 2022, Art. N° 105391

Visites 164

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues